ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,455Medicare Part D Prescriptions Filled, Including Refills

Rank: 208 out of 973

$584K Total Retail Price of All Prescriptions

Rank: 89 out of 973

237 Patients Receiving at Least One Drug in Part D
78%Patients 65 Years and Older
95% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Kansas
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 237 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

35% of this provider’s 237 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

2% of this provider’s 6,848 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

33% of this provider’s prescriptions were for brand-name drugs, compared to an average of 22%.

Prescription Price

$69 was the average price of a prescription from this provider, compared to $51 among peers.

Prescriptions per Patient

36 is the average number of prescriptions (including refills) per patient, compared to an average of 21.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Kansas
HYDROCODONE-ACETAMINOPHEN 375 241 S3 1 4
ALENDRONATE SODIUM 309 308 2 24
SIMVASTATIN 307 279 3 1
ATORVASTATIN CALCIUM 274 260 4 15
AMLODIPINE BESYLATE 272 204 5 7
NEXIUM 216 193 6 30
OMEPRAZOLE 198 158 7 5
METFORMIN HCL 190 172 8 8
ZOLPIDEM TARTRATE 180 146 9 20
LOSARTAN-HYDROCHLOROTHIAZIDE 174 154 10 46
LOSARTAN POTASSIUM 156 143 11 19
BYSTOLIC 153 136 12 110
AMOXICILLIN 136 118 13 101
TAMSULOSIN HCL 130 101 14 28
FLUTICASONE PROPIONATE 121 93 15 35
LISINOPRIL-HYDROCHLOROTHIAZIDE 105 70 16 25
NAMENDA 99 99 17 31
PROAIR HFA 98 76 18 54
MELOXICAM 94 72 19 23
LISINOPRIL 89 59 20 3
TRICOR 86 56 21 143
DIOVAN 84 81 22 63
DIOVAN HCT 82 75 23 145
AVODART 82 60 23 218
CARVEDILOL 80 72 25 27
GABAPENTIN 78 68 26 12
SPIRIVA 78 53 26 73
ALLOPURINOL 77 74 28 29
CELEBREX 73 73 29 91
FUROSEMIDE 70 53 30 6
LEVOTHYROXINE SODIUM 69 42 31 2
ACTONEL 66 56 32 236
JANUVIA 65 58 33 88
LOPERAMIDE 59 53 34 260
PRAMIPEXOLE DIHYDROCHLORIDE 59 53 34 152
AZELASTINE HCL 58 52 36 345
LOVAZA 58 56 36 183
PREDNISONE 58 48 36 33
MEGESTROL ACETATE 58 58 R 36 188
IBUPROFEN 57 34 40 102
MICARDIS HCT 56 55 41 265
TRIAMCINOLONE ACETONIDE 55 50 42 120
METOPROLOL SUCCINATE 52 47 43 17
LANSOPRAZOLE 52 51 43 155
FENOFIBRATE 51 29 45 77
LEVOFLOXACIN 51 46 45 84
MECLIZINE HCL 51 50 45 211
SINGULAIR 50 47 48 106
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.